Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PANThEON phase III trial in advanced pancreatic cancer
2024-515214-41-00Phase 3Authorised
- Sponsor
- G.O.N.O. - Gruppo Oncologico del Nord Ovest
- Start
- Jan 2025
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of gemcitabine, paclitaxel, irinotecan, fluorouracil, oxaliplatin and 1 more in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by G.O.N.O. - Gruppo Oncologico del Nord Ovest. Primary endpoint: Overall survival. Planned start Jan 2025; status: authorised.
02
Drugs
gemcitabinepaclitaxelirinotecanfluorouraciloxaliplatin
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2024-515214-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515214-41-00.